McCourt Marion sold $544K of REGN

McCourt Marion (EVP Commercial) sold 566 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $960.25 ($952.79–$971.93, $0.54M total) across 13 trades on 2026-11-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · McCourt Marion
Published Nov 18, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REGN
Neutral
medium confidence
Mentioned
$REGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNNeutralLow
01

Why it matters

This provides incremental transparency on insider activity but does not disclose operational, financial, or regulatory changes for Regeneron.

02

Market read

For traders, the main use is monitoring insider behavior and potential sentiment, but the 10b5-1 framing suggests limited fundamental implication.

03

What to watch

The sale is spread across 13 trades and explicitly tied to a pre-arranged 10b5-1 plan, which often reflects liquidity planning rather than new negative information.

Relevance 4/10Novelty 3/10Timing: filed 2026-11-18, covering sales executed 2026-11-16

Background

The article is a SEC Form 4 insider transaction disclosure for Regeneron, reporting an open-market sale by EVP Commercial McCourt Marion.

Company-level read

Ticker impact

$REGNNeutralMedium confidence
Context

Regeneron EVP Commercial McCourt Marion sold about $543.5K of REGN shares via an open-market sale under a pre-arranged 10b5-1 plan on 2026-11-16.

Expected impact

Likely modest near-term sentiment drag, with most of the move risk fading as the market treats it as planned 10b5-1 selling.

Evidence & confidence

The filing is a Form 4 insider sale, but it explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Biopharma sector read-through is limited because this is a single-company planned insider sale, not a clinical, regulatory, or guidance catalyst.

No clear regional spillover expected from a sub-$1M planned insider transaction.

Minimal global relevance; this is a US-listed issuer Form 4 disclosure.

Counterpoint

Traders may treat any insider selling by a top commercial executive as a bearish signal regardless of 10b5-1, especially if paired with other negative company signals not mentioned here.

Key entities

  • REGN

    Regeneron Pharmaceuticals, Inc., the company whose shares were sold in the Form 4.

  • McCourt Marion

    EVP Commercial who sold 566 shares across 13 trades under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REGNMed

These patients struggle with runaway bones. Finally there’s hope

The FDA approved two new treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Regeneron's garetosmab (Pasatru) and Mirum's zilurgisertib (Atebrioz) reduce abnormal bone growth. FOP affects about 900 people worldwide, with limited mobility and shortened lifespans. Trials for pediatric use are ongoing.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.